Rankings
▼
Calendar
PBYI Q1 2021 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena
PBYI
Puma Biotechnology, Inc.
$299M
Q1 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$98M
+91.7% YoY
Gross Profit
$69M
69.9% margin
Operating Income
$20M
20.5% margin
Net Income
$17M
16.8% margin
EPS (Diluted)
$0.40
QoQ Revenue Growth
+86.8%
Cash Flow
Operating Cash Flow
$16M
Free Cash Flow
$16M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$259M
Total Liabilities
$242M
Stockholders' Equity
$16M
Cash & Equivalents
$96M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$98M
$51M
+91.7%
Gross Profit
$69M
$42M
+62.8%
Operating Income
$20M
-$14M
+241.4%
Net Income
$17M
-$17M
+197.6%
Revenue Segments
License
$3M
52%
Royalty
$2M
48%
← FY 2021
All Quarters
Q2 2021 →